Your English writing platform
Discover LudwigSuggestions(2)
Exact(1)
As illustrated in figure 2A, patients in the laquinimod 0.5 and 1 mg groups entered clinical remission earlier than those in the pooled placebo group.
Similar(59)
All variables for which P < 0.1 in the univariate Cox models and/or in the baseline comparisons between the Low- and High-Mg groups were further entered into multivariate Cox models.
Patients were evaluated at week 16, and those with less than 5% improvement in tender and swollen joint count were switched to another treatment arm: patients receiving placebo entered the ustekinumab 45 mg group, and patients treated with ustekinumab 45 mg entered the ustekinumab 90 mg group.
Above these variables, HbA1c for which P < 0.10 in the baseline comparisons between the Low- and High-Mg groups (Table 1) were further entered into the multivariate Cox models, which showed that patients in the Low-Mg group were at a 2.12-fold higher risk of developing ESRD than were those in the High-Mg group (95% CI 1.28 3.51; P = 0.004) (Table 2).
Patients were allowed to enter early escape (Group 1 added golimumab 50 mg, Group 2 increased golimumab to 100 mg, Group 3 continued golimumab 100 mg) based on swollen/tender joint counts at week 14.
Group A; ondansetron 4 mg group.
Group C; ramosetron 0.3 mg group.
Group B; ondansetron 8 mg group.
These groups were entered in other registers.
Animals had received vehicle (n=21) or AM404 (2-mg and 10-mg groups combined, n=42) prior to extinction training (ie, 48 h prior to reinstatement).
At week 16, patients who had less than a 20% improvement from baseline in both total back pain and morning stiffness entered an early escape arm in which patients in the placebo group received golimumab 50 mg and patients in the golimumab 50-mg group had their dose increased to 100 mg.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com